Cargando…
Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
BACKGROUND: Although osimertinib was approved as adjuvant therapy for lung cancer patients with EGFR mutation in various countries, there is still some ongoing debate as osimertinib has been approved based on disease-free survival (DFS) rather than overall survival (OS). We curated a case series in...
Autores principales: | Osoegawa, Atsushi, Karashima, Takashi, Takumi, Yohei, Sato, Takahiro, Abe, Miyuki, Hashimoto, Takafumi, Sugio, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636461/ https://www.ncbi.nlm.nih.gov/pubmed/37969303 http://dx.doi.org/10.21037/jtd-23-537 |
Ejemplares similares
-
Significance of programmed death‐ligand 1 expression in resected lung cancer and its relationship with
EGFR
mutation
por: Osoegawa, Atsushi, et al.
Publicado: (2023) -
Giant benign intrathoracic schwannoma: a decade-long progression towards fatality
por: Miyawaki, Michiyo, et al.
Publicado: (2023) -
Tracheal injury from dog bite in a child
por: Miyawaki, Michiyo, et al.
Publicado: (2023) -
The clinical manifestations and treatment of male breast cancer: a report of three cases
por: Suehiro, Shuji, et al.
Publicado: (2015) -
Clinical significance of part-solid lung cancer in the eighth edition TNM staging system
por: Okamoto, Tatsuro, et al.
Publicado: (2021)